Literature DB >> 19437324

CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome.

Nadia Dakka1, Hicham Bellaoui, Nadia Bouzid, Mohammed Khattab, Youssef Bakri, Abdelaziz Benjouad.   

Abstract

CD10 and CD34 expression in 86 Moroccan children with acute lymphoblastic leukemias (ALL) and the relevance to prognosis, diagnosis, and outcome during a 5-year follow-up were examined. At diagnosis, 57% of patients had CD10(+) blasts, while 35% had CD34(+) blasts. The CD10(+) blast frequency was much higher (80%) in B-ALL than in T-ALL (20%). The frequency of CD34(+) blasts was higher in B-ALL (48%) compared to T-ALL (16%). The 5-year survival curves showed that children with CD10(+) B-ALL had a significantly longer survival rate than those with CD10(-), as observed for T-ALL. The survival rate of B-ALL expressing CD34 was higher than that of CD34(-). Thus, CD34 and CD10 expression may have prognostic value and is associated with a better clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437324     DOI: 10.1080/07357900902897557

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  9 in total

1.  Applicability of gene expression profile of childhood acute lymphoblastic leukemia at diagnosis and at the end of the induction phase of chemotherapy at a cancer hospital in the state of Goiás (Brazil).

Authors:  Lysa B Minasi; Fernanda R Godoy; Daniela de M e Silva; Thaís C Vieira; Cláudio C da Silva; Aparecido D da Cruz
Journal:  Tumour Biol       Date:  2013-09-20

2.  Immunophenotypic characteristics of T lineage acute lymphoblastic leukemia: absence of immaturity markers-TdT, CD34 and HLADR is not uncommon.

Authors:  Richa Gupta; Neha Garg; Mrinalini Kotru; Dilip Kumar; Rajesh Pathak
Journal:  Am J Blood Res       Date:  2022-02-15

3.  Bone-forming perivascular cells: Cellular heterogeneity and use for tissue repair.

Authors:  Jiajia Xu; Yiyun Wang; Mario A Gomez-Salazar; Ginny Ching-Yun Hsu; Stefano Negri; Zhao Li; Winters Hardy; Lijun Ding; Bruno Peault; Aaron W James
Journal:  Stem Cells       Date:  2021-07-12       Impact factor: 6.277

4.  CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis.

Authors:  Neha Garg; Richa Gupta; Mrinalini Kotru
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

5.  The Expression and Prognostic Impact of CD95 Death Receptor and CD20, CD34 and CD44 Differentiation Markers in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Fatemeh M Kamazani; Gholamreza Bahoush-Mehdiabadi; Mahnaz Aghaeipour; Shahram Vaeli; Zahra Amirghofran
Journal:  Iran J Pediatr       Date:  2014-05-21       Impact factor: 0.364

6.  Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience.

Authors:  Nishit Gupta; Ravikiran Pawar; Sambhunath Banerjee; Subhajit Brahma; Asish Rath; Sundar Shewale; Mayur Parihar; Manish Singh; S R Arun; Shekhar Krishnan; Arpita Bhatacharyya; Anirban Das; Jeevan Kumar; Saurabh Bhave; Vivek Radhakrishnan; Reena Nair; Mammen Chandy; Neeraj Arora; Deepak Mishra
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

Review 7.  Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia.

Authors:  Narges Aberuyi; Soheila Rahgozar; Elaheh Sadat Ghodousi; Kamran Ghaedi
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

8.  Frequency of CD34 and CD10 Expression in Adolescent and Young Adult Patients Having Precursor B-cell Acute Lymphoblastic Leukemia and Its Correlation With Clinical Outcomes: A Single-Center Study.

Authors:  Munawar Ali Shah; Usman Ahmad; Muhammad Tariq Mahmood; Asad H Ahmad; Muhammad Abu Bakar
Journal:  Cureus       Date:  2022-01-15

9.  CD10 expression in the neuroendocrine carcinoma component of endometrial mixed carcinoma: association with long survival.

Authors:  Karina Uehara; Fukino Ikehara; Yasuka Tanabe; Iwao Nakazato; Mariko Oshiro; Morihiko Inamine; Takao Kinjo
Journal:  Diagn Pathol       Date:  2016-02-01       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.